Neisvac-C

N. meningitidis Group C (Strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid, the active ingredient in Neisvac-C, is a meningococcal conjugate vaccine presented as a suspension for injection for intramuscular use. It prevents invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk, including adolescents and adults.

GNH USA supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and health‑care providers worldwide.

Neisvac‑C is used to induce immunity against meningococcal disease caused by serogroup C.

Invasive meningococcal disease (serogroup C): induces protective antibodies that prevent infection. Meningococcal carriage in adolescents: reduces nasopharyngeal carriage and limits transmission. Outbreak response in high‑risk settings: provides rapid immunization to control spread of serogroup C disease.

Common and serious adverse reactions have been reported following administration of Neisvac‑C.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade fever within 24‑48 hours. - Headache: mild headache reported post‑vaccination. - Fatigue: temporary feeling of tiredness. - Myalgia: muscle aches around the injection area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - Seizures: infrequent occurrence, especially in febrile infants. - Hypotension: sudden drop in blood pressure after injection. - Severe local reaction: extensive swelling or necrosis at the site.

Before administering Neisvac‑C, consider the following precautions and warnings. - Allergy assessment: avoid use in individuals with a known severe hypersensitivity to any vaccine component or tetanus toxoid. - Acute illness: postpone vaccination in persons with moderate or severe febrile illness until recovery. - Immunocompromised patients: vaccine may elicit reduced immune response; assess benefit‑risk. - Pregnancy and lactation: safety has not been established; use only if potential benefit justifies the potential risk. - Age considerations: approved for use in individuals aged 2 years and older; follow local immunization schedules. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac‑C may interact with other agents that affect immune function or vaccine efficacy.

Major Interactions (Avoid): - Concurrent administration of other meningococcal conjugate vaccines: may lead to immune interference and reduced antibody response. - Live vaccines given within 4 weeks: may compromise immune response to either vaccine.

Moderate Interactions (Monitor Closely): - Immunoglobulin or blood products given within 3 weeks: can diminish vaccine‑induced antibody levels. - Immunosuppressive therapy: may lower immunogenicity, requiring assessment of protective titers. - Antipyretics taken prophylactically: may slightly reduce antibody response; advise use only for symptom relief.